Nifty
Sensex
:
:
24213.30
79476.63
217.95 (0.91%)
694.39 (0.88%)

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543963 | NSE: Not Listed

60.28
05-Nov-2024
  • Open
  • High
  • Low
  • Previous Close
  •  61.7
  •  61.7
  •  59.01
  •  60.02
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  216000
  •  12988890
  •  80.90
  •  39.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 70.23
  • 11.33
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 71.58
  • N/A
  • 2.37

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.97%
  • 1.15%
  • 40.12%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 3.76%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -

Quarterly Results

N/A

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

Top Investors:

News Update:


  • Shelter Pharma secures order from FIRSTVET Veterinary Medicines Trading
    30th Oct 2024, 10:28 AM

    The said order is expected to be executed within 2 months

    Read More
  • Shelter Pharma secures order from Genet International
    29th Oct 2024, 15:42 PM

    The total order is worth $12,500

    Read More
  • Shelter Pharma secures order from Taha Drugs & Chemical
    23rd Oct 2024, 15:29 PM

    Total order is worth $80,000

    Read More
  • Shelter Pharma secures order worth $17,700
    18th Sep 2024, 14:41 PM

    The order is to be executed within 2 months

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.